The choice of allogeneic or autologous hematopoietic transplantation for NHL

References

• Greer JP, Macon WR, McCurley TL Non-Hodgkin lymphomas. In: Lee GR, Foerster J, Lukens J et al., editors. Wintrobe:r clinical hematology. Baltimore: Williams and Wilkins, 1999: 2447–537.
   Google Scholar
• Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer .7 Clin 2002;52: 23–47.
   Google Scholar
• Gale RP, Champlin RE. How does bone marrow transplan-tation cure leukemia? Lancet 1984;2:28–9.
   PubMed Web of Science ®Google Scholar
• Weiden PL, Sullivan KM, Flournoy N et al. for the SeattleMarrow Transplant Team. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl 7 Med 1981;304: 1529–33.
   Google Scholar
• Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555–62.
   PubMed Web of Science ®Google Scholar
• Sullivan KM, Storb R, Buckner CD et al. Graft-versus-hostdisease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl .7 Med 1989;320: 828–34.
   Google Scholar
• Khouri IF, Keating MJ, Vriesendorp HM et al. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. 7 Clin Oncol 1994;12:748–58.
   PubMed Web of Science ®Google Scholar
• Rabinowe SN, Soiffer RJ, Gribben JG et al. Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. Blood 1993;82:1366–76.
   PubMed Web of Science ®Google Scholar
• Jones RJ, Ambinder RF, Piantadosi S et al. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 1991;77:649–53.
   PubMed Web of Science ®Google Scholar
• Mehta J, Powles R, Singhal S et al. Clinical and hematologic response of chronic lymphocytic and prolymphocytic leukemia persisting after allogeneic marrow transplantation with the onset of graft-versus-host disease: possible role of graft-versus-leukemia. Bone Marrow Transplant 1996; 17:371–5.
   PubMed Web of Science ®Google Scholar
• Van Besien KW, Mehra RC, Giralt SA et al. Allogeneic bone marrow transplantation for poor prognosis lymphoma: response, toxicity and survival depend on disease histology. Am y Med 1996;100:299–307.
   PubMed Web of Science ®Google Scholar
• Chopra R, Goldstone AH, Pearce R et al. Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group Registry data. y Clin Oncol 1992;10:1690–5.
   PubMed Web of Science ®Google Scholar
• Van Besien KW, de Lima M, Giralt SA et al. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplant 1997;19:977–82.
   PubMed Web of Science ®Google Scholar
• Rondón G, Giralt S, Huh Y et al. Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transplant 1996;18:669–72.
   PubMed Web of Science ®Google Scholar
• Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in mar-row grafted patients. Blood 1995;86:2041–50.
   PubMed Web of Science ®Google Scholar
• Michallet M, Corront B, Hollard D et al. Allogeneic bone marrow transplantation in chronic lymphocytic leukemia:
   Google Scholar
• cases. Report from the EBMTG. Bone Marrow Transplant 1991;7:275–9.
   Google Scholar
• Khouri I, Keating M, Körbling M et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. y Clin Oncol 1998;16:2817–24.
   PubMed Web of Science ®Google Scholar
• Antin JH, Ferrara JLM. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992;80:2964–8.
   PubMed Web of Science ®Google Scholar
• Hill GR, Crawford JM, Cooke KR et al. Total body irradia-tion and acute graft-versus-host disease: The role of gastro-intestinal damage and inflammatory cytokines. Blood 1997; 90:3204–13.
   PubMed Web of Science ®Google Scholar
• Surbone A, Armitage JO, Gale RP. Autotransplantation in lymphoma: better therapy or healthier patients? [Editorial] Ann Intern Med 1991;114:1059–60.
   PubMed Web of Science ®Google Scholar
• Armitage JO. Drug therapy: treatment of non-Hodgkin's lymphoma. N Engl .7 Med 1992;328: 1023–30.
   Google Scholar
• Philip T, Guglielmi C, Hagenbeek A et al. Autologous bonemarrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy sensitive non-Hodgkin's lymphoma. N Engl y Med 1995;333:1540–5.
   PubMed Web of Science ®Google Scholar
• Guglielmi C, Gomez F, Philip T et al. Time to relapse has prognostic value in patients with aggressive lym-phoma enrolled onto the Parma trial. y Clin Oncol 1998;16:3264–9.
   PubMed Web of Science ®Google Scholar
• Blay J, Gomez F, Sebban C et al. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the Parma trial. Parma Group. Blood 1998;92:3562–8.
   Google Scholar
• Colombat P, Gorin NC, Lemonnier MP et al. The role of autologous bone marrow transplantation in 46 adult patients with non-Hodgkin's lymphomas. y Clin Oncol 1990;8:630–7.
   PubMed Web of Science ®Google Scholar
• Weisdorf DJ, Haake R, Miller WJ et al. Autologous bone marrow transplantation for progressive non-Hodgkin's lymphoma: clinical impact of immunophenotype and in vitro purging. Bone Marrow Transplant 1991;8:135–42.
   PubMed Web of Science ®Google Scholar
• Lazarus HM, Crilley P, Ciobanu N et al. High-dose carmus-tine, etoposide, and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma. Clin Oncol1992;10:1682–9.
   Web of Science ®Google Scholar
• Vose JM, Anderson JR, Kessinger A et al. High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma. y Clin Oncol1993;11:1846–51.
   PubMed Web of Science ®Google Scholar
• Wheeler C, Strawderman M, Ayash L et al. Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lym-phoma with cyclophosphamide, carmustine, and etoposide. y Clin Onco/1993;11:1085–91.
   PubMed Web of Science ®Google Scholar
• Mills W, Chopra R, McMillan A et al. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. Clin Oncol 1995;13:588–95.
   Web of Science ®Google Scholar
• van Besien K, Tabocoff J, Rodriguez M et al. High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity. Bone Marrow Transplant 1995;15:549–55.
   PubMed Web of Science ®Google Scholar
• Ladenstein R, Pearce R, Hartmann 0 et al. High-dose chemotherapy with autologous bone marrow rescue in children with poor-risk Burkitt's lymphoma: a report from the European Lymphoma Bone Marrow Transplantation Registry. Blood 1997;90: 2921–30.
   Google Scholar
• Petersen FB, Appelbaum FR, Hill R et al. Autologous mar-row transplantation for malignant lymphoma: a report of 101 cases from Seattle. y Clin Oncol 1990;8:638–47.
   PubMed Web of Science ®Google Scholar
• Rapoport AP, Lifton R, Constine LS et al. Auto-transplantation for relapsed or refractory non-Hodgkin's lymphoma (NHL): long-term follow-up and analysis of prognostic factors. Bone Marrow Transplant 1997;19: 883–90.
   PubMed Web of Science ®Google Scholar
• Phillips GL, Fay JW, Herzig RH et al. The treatment of pro-gressive non-Hodgkin's lymphoma with intensive chemo-radiotherapy and autologous marrow transplantation. Blood 1990;75:831–8.
   PubMed Web of Science ®Google Scholar
• Weaver CH, Petersen FB, Appelbaum FR et al. High-dose fractionated total-body irradiation, etoposide, and cyclo-phosphamide followed by autologous stem-cell support in patients with malignant lymphoma. y Gun Oncol 1994;12:2559–66.
   PubMed Web of Science ®Google Scholar
• Shipp MA, Abeloff MD, Antman KH et al. International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury. y Clin Oncol 1999;17:423–9.
   PubMed Web of Science ®Google Scholar
• Haioun C, Lepage E, Gisselbrecht C et al. Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. Groupe d'Etude des Lymphomes de l'Adulte.Clin Oncol 1994;12:2543–51.
   PubMed Web of Science ®Google Scholar
• Haioun C, Lepage E, Gisselbrecht C et al. Benefit of auto-logous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lym-phoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte study. y Clin Oncol 1997;15:1131–7.
   PubMed Web of Science ®Google Scholar
• Haioun C, Lepage E, Gisselbrecht C et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol�a groupe d'Etude des Lymphomes de l'Adulte study. y Clin Oncol 2000;18:3025–30.
   PubMed Web of Science ®Google Scholar
• Santini G, Salvagno L, Leoni P et al. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group. y Clin Oncol 1998;16:2796–802.
   PubMed Web of Science ®Google Scholar
• Reyes F, Lepage E, Morel P et al. Failure of first-line induc-tive high-dose chemotherapy (HDC) in poor-risk patients (PTS) with aggressive lymphoma: updated results of the randomized LNH93-3 study. Blood 1997;90:594a.
   Web of Science ®Google Scholar
• Verdonck LF, van Putten WL, Hagenbeek A et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl y Med 1995;332:1045–51.
   PubMed Web of Science ®Google Scholar
• Cabanillas F, Hagemeister FB, McLaughlin P et al. Results of MIME salvage regimen for recurrent or refractory lym-phoma. y Clin Oncol 1987;5:407–12.
   PubMed Web of Science ®Google Scholar
• Vose J, Zhang M-J, Rowlings P et al. Autologous transplanta-tion for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the auto-logous blood and marrow transplant registry. y Clin Oncol 2001;19:406–13.
   PubMed Web of Science ®Google Scholar
• Sweetenham JW, Pearce R, Taghipour G et al. Adult Burkitt's and Burkitt-like non-Hodgkin's lymphoma. Outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: results from the European Group for Bone Marrow Transplantation. y Clin Oncol1996;14:2465–72
   Google Scholar
• Sweetenham JW, Liberti G, Pearce R et al. High-dose therapy and autologous bone marrow transplantation for adult patients with lymphoblastic lymphoma: Results of the European Group for Bone Marrow Transplantation. y Clin Oncol 1994;12:1358–65.
   PubMed Web of Science ®Google Scholar
• Sharp JG, Kessinger A, Mann S et al. Outcome of high-dose therapy and autologous transplantation in non-Hodgkin's lymphoma based on the presence of tumor in the marrow or infused hematopoietic harvest. y Clin Oncol 1996;14:219–19.
   Web of Science ®Google Scholar
• Williams CD, Goldstone AH, Pearce RM et al. Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin's lymphoma: a case-matched comparison with unpurged cases by the European Blood and Marrow Transplant Registry. y Clin Oncol 1996;14:2454–64.
   PubMed Web of Science ®Google Scholar
• Ratanatharathorn V, Uberti J, Karanes C et al. Prospective comparative trial of autologous versus allogeneic bone mar-row transplantation in patients with non-Hodgkin's lym-phoma. Blood 1994;84:1050–5.
   PubMed Web of Science ®Google Scholar
• Dann EJ, Daugherty CK, Larson RA. Allogeneic bone mar-row transplantation for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma. Bone Marrow Transplant 1997;20:369–74.
   Google Scholar
• Van Besien K, Thall P, Körbling M et al. Allogeneic trans-plantation for recurrent or refractory non-Hodgkin's lym-phoma with poor prognostic features after conditioning with thiotepa, busulfan and cyclophosphamide: experience in 44 consecutive patients. Biol Blood Marrow Transplant 1997;3:150–6.
   PubMedGoogle Scholar
• Demirer T, Weaver CH, Buckner CD et al. High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy. y Clin.Oncol1995;13:596–602.
   PubMed Web of Science ®Google Scholar
• Phillips GL, Herzig RH, Lazarus HM et al. High-dose chemotherapy, fractionated total-body irradiation, and allo-geneic marrow transplantation for malignant lymphoma. Clin Oncol 1996;4:480–8.
   Google Scholar
• Peniket AJ, Ruiz de Elvira MC, Taghipour G et al. Allogeneic transplantation for lymphoma produces a lower relapse rate than autologous transplantation but survival is worse because of higher treatment related mortality: a report of 764 cases from the EBMT lymphoma registry. Blood 1997;90:255a.
   Google Scholar
• de Witte T, Awwad B, Boezeman J et al. Role of allogeneic bonemarrow transplantation in adolescent or adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma in first remission. Bone Marrow Transplant 1994;14:767–74.
   PubMed Web of Science ®Google Scholar
• Troussard X, Leblond V, Kuentz M et al. Allogeneic bone marrow transplantation in adults with Burkitt's lymphoma or acute lymphoblastic leukemia in first complete remis-sion. 7 Clin Oncol 1990;8:809–12.
   PubMed Web of Science ®Google Scholar
• Dhedin N, Giraudier S, Gaulard P et al. Allogeneic bone marrow transplantation in aggressive non-Hodgkin's lym-phoma (excluding Burkitt and lymphoblastic lymphoma): A series of 73 patients from the SFGM database. Br yHematol 1999;107:154–61.
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Van Besien K, Khouri I et al. Carmustine, etoposide, cytarabine and melphalan as a preparative regi-men for allogeneic transplantation for high-risk malignant lymphoma. Ann Oncol 1999;10:527–32.
   PubMed Web of Science ®Google Scholar
• Khouri IF, Saliba R, Giralt S et al. Long term remission and low mortality achieved with cisplatin, fludarabine, cytara-bine nonablative preparative regimen and allogeneic stem cell transplantation (AST) for histologically aggressive non-Hodgkins lymphoma (NHL). Blood 2001;98:190a.
   Web of Science ®Google Scholar
• Argatoff LH, Connors JM, Klasa RJ et al. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood 1997;89:2067–78.
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Unterhalt M, Hermann R et al. Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: Results of a prospective comparative analysis of the German low-grade lymphoma study group. 7 Clin Oncol 1998;16: 1922–1930.
   Google Scholar
• Majlis A, Pugh WC, Rodriguez MA et al. Mantle cell lymphoma: Correlation of clinical outcome and biologic features with three histologic variants. 7 Clin Oncol 1997;15:1664–71.
   PubMed Web of Science ®Google Scholar
• Freedman AS, Neuberg D, Gribben JG et al. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. 7 Clin Oncol 1998;16: 13–18.
   Google Scholar
• Khouri IF, Romaguera J, Kantarjian H et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: An active regimen for aggressive mantle-cell lymphoma. 7 Clin Oncol 1998;16: 3803–9.
   Google Scholar
• Adkins D, Brown R, Goodnough LT et al. Treatment of resistant mantle cell lymphoma with allogeneic bone mar-row transplantation. Bone Marrow Transplant 1998;21: 97–9.
   PubMed Web of Science ®Google Scholar
• Corradini P, Ladetto M, Astolfi M et al. Clinical and molec-ular remission after allogeneic blood cell transplantation in a patient with mantle-cell lymphoma. Br 7 Hematol 1996;94:376–8.
   PubMed Web of Science ®Google Scholar
• Khouri I, Lee M-S, Romaguera J et al. Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy. Ann Oncol 1999;10:1293–9.
   PubMed Web of Science ®Google Scholar
• Horning SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993;20 (Suppl 5): 75–88.
   PubMed Web of Science ®Google Scholar
• Horning SJ. Treatment approaches to low grade lym-phomas. Blood 1994;83:881–4.
   PubMed Web of Science ®Google Scholar
• Romaguera JE, McLaughlin P, North L et al. Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: a risk model. 7 Clin Oncol1991;9:762–9.
   PubMed Web of Science ®Google Scholar
• Johnson PWM, Rohatiner AZS, Whelan JS et at Patterns of survival in patients with recurrent follicular lymphoma: a 20 year study from a single center. 7 Clin 0nco11995;13:140–7.
   PubMed Web of Science ®Google Scholar
• Rohatiner AZ, Johnson PW, Price CG et al. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. Clin Oncol1994;12:1177–84.
   Web of Science ®Google Scholar
• Bierman PJ, Vose JM, Anderson JR et al. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. yClin Noll 997;15:445–50.
   Google Scholar
• Freedman AS, Neuberg D, Mauch P et al. Long term follow up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999;94:3325–33.
   PubMed Web of Science ®Google Scholar
• Colombat P, Donadio D, Fouillard L et al. Value of auto-logous bone marrow transplantation in follicular lymphoma: a France Autogreffe retrospective study of 42 patients. Bone Marrow Transplant 1994;13:157–62.
   PubMed Web of Science ®Google Scholar
• Bastion Y, Haioun C, Sonet A et al. Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. Blood 1995;86:3257–62.
   PubMed Web of Science ®Google Scholar
• Cao TM, Horning SJ, Negrin RS et al. High-dose therapy and autologous hematopoietic cell transplantation for follicular lymphoma beyond first remission: The Stanford University Experience. Biol Blood Marrow Transplant 2001;7:294–301.
   PubMed Web of Science ®Google Scholar
• Freedman A, Gribben J, Neuberg D et al. High dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 1996;88:2780–6.
   PubMed Web of Science ®Google Scholar
• Horning SJ, Negrin RS, Hoppe RT et al. High dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase clinical trial. Blood 2001;97:404–9.
   PubMed Web of Science ®Google Scholar
• Martin D, Moos M, Voso M et al. High dose therapy with peripheral stem cell transplantation in patients with low-grade non-Hodgkin's lymphoma. Blood 1998;92 (Suppl 1): 460a.
   Google Scholar
• Micallet M, Lillington DM, Apostolidis J et al. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malig-nancies. 7 Clin Oncol 2000;18: 947–55.
   Google Scholar
• Miller JS, Arthur DC, Litz CE et al. Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy. Blood 1994;83:3780–6.
   PubMed Web of Science ®Google Scholar
• Schouten HC, Kvaloy S, Sydes M et al. The CUP trial: a randomized study analyzing the efficacy of high dosetherapy and purging in low-grade non-Hodgkin's lymphoma (NHL). Ann Oncol 2000;11:91–4.
   PubMed Web of Science ®Google Scholar
• Stein RS, Greer JP, Goodman S et al. High-dose therapy with autologous or allogeneic transplantation as salvage therapy for small cleaved cell lymphoma of follicular center cell origin. Bone Marrow Transplant 1999;23:227–33.
   PubMed Web of Science ®Google Scholar
• Gribben J, Neuberg D, Freedman A et al. Detection by poly-merase chain reaction of residual cells with the bc1-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation of B-cell lymphoma. Blood 1993;81:3449–57.
   PubMed Web of Science ®Google Scholar
• Zwicky CS, Maddocks AB, Anderson N et al. Eradication of polymerase chain reaction immunoglobulin gene rearrangement in non-Hodgkin's lymphoma is associated with decreased relapse after autologous bone marrow transplantation. Blood 1996;88:3314–22.
   PubMed Web of Science ®Google Scholar
• Moos M, Schulz R, Martin S et al. The remission status before and the PCR status after high-dose therapy with peripheral blood stem-cell support are prognostic factors for relapse-free survival in patients with follicular non-Hodgkin's lymphoma. Leukemia 1998;12:1971–6.
   PubMed Web of Science ®Google Scholar
• Press 0, Eary J, Applebaum F et al. Phase II trial of 131�B1 (anti CD20) antibody therapy with autologous stem cell transplantation for relapsed B-cell lymphomas. Lancet 1995;346: 336–40.
   Google Scholar
• Liu S, Eary J, Petersdorf S et al. Follow-up of relapsed B-celllymphoma patients treated with iodine-131�labeled anti-CD20 antibody and autologous stem-cell rescue. 7 Clin Oncol 1998;16: 3270–8.
   Google Scholar
• Buckstein R, Imrie K, Spaner D et al. High frequency of molecular remissions associated with rituxan or interferonimmunotherapy following ASCT for follicular NHL. Blood 2000;96:3418a.
   Web of Science ®Google Scholar
• Magni M, DiNicola M, Devizzi L et al. Successful in vivo purging of CD 34 containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood 2000;96:869–9.
   Web of Science ®Google Scholar
• Klingemann HG, Grigg AP, Wilke-Boyd K et al. Treatment with recombinant interferon (alpha-2b) early after bone marrow transplantation in patients at high risk for relapse. Blood 1991;78:3306–11.
   PubMed Web of Science ®Google Scholar
• Van Besien KW, Khouri IF, Giralt SA et al. Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management. 7 Gun 0nco11995;13:1096–102.
   Google Scholar
• Van Besien K, Sobocinski KA, Rowlings PA et al. Allogeneic bone marrow transplantation for low-grade lymphoma. Blood 1998;92:1832–6.
   PubMed Web of Science ®Google Scholar
• Verdonck LF, Dekkar AW, Lokhorst HM et al. Allogeneic versus autologous bone marrow transplantation for refrac-tory and recurrent low-grade non-Hodgkin's lymphoma. Blood 1997;90:4201–5.
   PubMed Web of Science ®Google Scholar
• Khouri IF, Saliba R, Giralt S et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment related mortality. Blood 2001;98:3595–9.
   PubMed Web of Science ®Google Scholar
• Khouri I, Saliba R, Giralt S et al. Allogeneic hematopoietic transplantation for indolent lymphomas: Improved outcome with non-myeloablative versus high dose chemotherapy (HDC T) regimens. Blood 2000;96:853a.
   Google Scholar